Applied Biologics treats first patient in pivotal BIOxHEAL diabetic foot ulcer trial
Applied Biologics begins Phase 3 testing of BIOxHEAL for diabetic foot ulcers. Explore its wound-healing potential and trial milestones.
Pharma & Biotech
Pharma & Biotech
EB613 oral osteoporosis treatment gains momentum as Entera Bio outlines 900-patient Phase 3 trial
Entera Bio reports stronger EB613 bone density gains in Phase 2 osteoporosis analysis. Explore the results and upcoming Phase 3 trial plans.
Pharma & Biotech
Can Soufflé’s REMEDY platform solve RNA drug delivery challenges beyond the liver?
Soufflé secures $135 million as its FSHD RNA therapy trial recruits patients. Examine the REMEDY platform, Bayer partnership and clinical risks.
Pharma & Biotech
Aulos saw lung tumors shrink up to 48% in early testing. Can its IL-2 combination deliver more?
Aulos Bioscience will present Phase 2 findings for imneskibart, low-dose interleukin-2 and avelumab in checkpoint-resistant lung adenocarcinoma. Earlier findings showed tumor shrinkage in a small cohort, but the forthcoming ESMO data must establish response rates, durability and safety more clearly.
Pharma & Biotech
Can Alpha Cognition’s new manufacturing process strengthen ZUNVEYL market protection?
Alpha Cognition publishes a ZUNVEYL manufacturing patent application as sales grow, targeting process protection through 2045.
Pharma & Biotech
Why āshibio’s 40,000-patient ADO2 market estimate requires careful interpretation
āshibio's vantictumab activates bone resorption in 94% of patients. New ADO2 prevalence findings sharpen its clinical and safety questions.
Pharma & Biotech
GC Biopharma expands ALYGLO safety evidence amid growing US immunoglobulin sales
GC Biopharma will present expanded aggregation testing across 18 lots of five IVIG products and a new review of ALYGLO Phase 3 safety data. The analyses identify measurable molecular differences and provide additional safety context, but neither establishes comparative clinical superiority.
Pharma & Biotech
Can āshibio’s andecaliximab stop abnormal bone growth? An 86.2% flare-up reduction raises the stakes
āshibio reports 86.2% fewer FOP flare-ups with andecaliximab in early data, but placebo-controlled evidence remains pending.
Pharma & Biotech
China approves Foresee’s twice-yearly prostate cancer injection. Could it unlock a $123.85m milestone deal?
Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.
Pharma & Biotech
T-MAXIMUM’s off-the-shelf CAR-T shrank brain tumors in early testing. Can Phase 2 confirm the signal?
T-MAXIMUM has received FDA clearance to initiate a Phase 2 study of MT027 in brain metastases from lung and breast cancer. Early results in a small lung cancer cohort support further investigation, but clinical efficacy, neurological safety and manufacturing scalability remain unproven.